Sustained benefit with seralutinib treatment: a post-hoc analysis of the TORREY open-label extension

Sustained benefit with seralutinib treatment: a post-hoc analysis of the TORREY open-label extension

ERS – September 2024

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study